drugset / Trial / NCT02413281
A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users
RandomizedCrossoverDouble-blindTreatment
Summary
This study will evaluate the abuse potential of ALKS 5461.
Timeline
- Start
- 2015-03
- Primary completion
- 2015-09
- Completion
- 2015-09
Outcome
Met primary endpoint
paper Drug Liking Emax for all BUP/SAM doses were significantly lower than those observed for either buprenorphine dose alone. PMID 30102427 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Buprenorphine | Other / unclassified | 2 mg | Other |
| Comparator | Buprenorphine | Other / unclassified | 8 mg | Other |
| Comparator | Buprenorphine | Other / unclassified | 16 mg | Other |
| Subject | Samidorphan | Small molecule | 2 mg | Other |
| Subject | Samidorphan | Small molecule | 8 mg | Other |
| Subject | Samidorphan | Small molecule | 16 mg | Other |
Indications
No indication recorded.